The headline undersold it. The New York Times called this "new promise" on July 15. Fujirebio's Lumipulse G pTau217/β-Amyloid plasma ratio has been running in clinics for over a year, FDA-cleared in May 2025, available through Labcorp and Quest Diagnostics.
92% right when it says yes. In the 499-patient study behind the clearance, a positive result meant amyloid pathology was present 92% of the time. A negative result cleared it with 97% confidence. Getting numbers like that used to mean a PET scan or a spinal tap.
One test doesn't make a diagnosis. A positive p-tau217 result means amyloid is probably there. A neurologist still weighs it against cognitive testing and clinical history before anyone says the word Alzheimer's.
Your last physical skipped it on purpose. This test is cleared for adults 50 and older who already show signs of cognitive decline, run in a specialist setting. It's not a line item on a routine metabolic panel, and your GP isn't tacking it onto an annual physical.
Right now, this helps people already flagged for decline. Memory complaints, a referral, a family pushing for answers: that's the usual path to getting this ordered. If nobody suspects decline yet, this biomarker isn't on anyone's radar. Including yours.
Cognitive symptoms like brain fog or word-finding trouble sent you looking at blood tests in the first place? p-tau217 won't be on your panel. See blood test markers for brain fog for what your panel checks first.